Clinical pharmacokinetics of the diastereomers of arteether in healthy volunteers

Clinical Pharmacokinetics

Volumn 44, Issue 11, 2005, Pages 1191-1203

  Sabarinath, Sreedharan N ^a   Asthana, Omkar P ^a   Puri, Sunil K ^a   Srivastava, Kumkum ^a   Madhusudanan, Kunnath P ^a   Gupta, Ram C ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEETHER; EMAL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTEREOISOMER; ELECTROSPRAY; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; CELLS, CULTURED; ERYTHROCYTES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; VOLUNTARY WORKERS;

EID: 26944468309     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544110-00006     Document Type: Article

References (46)

1. Cheng F, Shen J, Luo X, et al. Molecular docking and 3-D-QSAR studies on the possible antimalarial mechanism of artemisinin analogues. Bioorg Med Chem 2002; 10: 2883-91
2. Price R, vanVugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60: 547-55
3. Shuhua X, Yuanqing Y, Qiqing Y, et al. Potential long-term toxicity of repeated orally administered doses of artemether in rats. Am J Trop Med Hyg 2002; 66: 30-4
4. Davidson DE. Role of arteether in the treatment of malaria and plans for further development. Trans R Soc Trop Med Hyg 1994; 88 Suppl. 1: 51-2
5. Ahton M, Gordi T, Hai TN, et al. Artemisinin pharmacokinetics in healthy adults after 250, 500, and 1000mg single oral doses. Biopharm Drug Dispos 1998; 19: 245-50
6. Li Q-G, Peggins JO, Fleckenstein LL, et al. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J Pharm Pharmacol 1998; 50: 173-82
7. Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 69-75
8. VanAgtmael MA, Cheng-Qi S, Qing JX, et al. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999; 12: 151-8
9. Tripathi R, Dutta GP, Vishwakarma RA. Comparison of antimalarial efficacy of α, β and α/β-arteether against Plasmodium cyanomolgi B infection in monkeys. Am J Trop Med Hyg 1991; 44: 560-3
10. Brossi A, Venugopalan B, Dominguez Gerpe L, et al. Arteether, a new antimalarial drug: synthesis and antimalarial properties. J Med Chem 1988; 31: 645-50
11. Singh C, Tiwari P. A one pot conversion of artemisinin to its ether derivatives. Tetrahedron Lett 2002; 43: 7235-7
12. Tripathi R, Vishwakarma RA, Dutta GP. Plasmodium fragile: efficacy of arteether (α/β) against cerebral malaria model. Exp Parasitol 1997; 87: 290-2
13. World Health Organisation (WHO). Review of application for inclusion of a drug in the WHO essential drugs list. CDS/RBM. Geneva: WHO, 2002
14. Asthana OP, Srivastava JS, Kamboj VP, et al. A multicentric study with arteether in patients of uncomplicated falciparum malaria. J Assoc Physicians India 2001; 49: 692-6
15. Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2003; 42: 1359-82
16. Isavadharm PJ, Nosten F, Kyle DE, et al. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol 1996; 42: 599-604
17. Batty KT, Ilett KF, Powel SM, et al. Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Am J Trop Med Hyg 2002; 66 (2): 130-6
18. Svensson USH, Sandstorm R, Carlborg O, et al. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1998; 27: 227-32
19. Karbwang J, Na-Bangchang K, Congpoung K, et al. Pharmacokinetics of oral artesunate in Thai patients with uncomplicated falciparum malaria. Clin Drug Invest 1998; 45: 597-600
20. Singh N, Shukla MM, Asthana OP, et al.. Effectiveness of α/β-arteether in clearing Plasmodium falciparum parasitemia in central India. Southeast Asian J Trop Med Public Health 1998; 29: 225-7
21. Mishra SK, Asthana OP, Mohanty S, et al. Effectiveness of α/β-arteether in acute falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89: 299-301
22. Kager PA, Schultz MJ, Zijlstra EE, et al. Arteether administration in humans: preliminary studies of pharmacokinetics, safety and tolerance. Trans R Soc Trop Med Hyg 1994; 88 Suppl. 1: 53-4
23. Hufford CD, Lee IS, ElSohly HN, et al. Structure elucidation and thermospray high performance liquid chromatography/mass spectroscopy of the microbial and mammalian metabolites of the antimalarial arteether. Pharm Res 1990; 7 (9): 923-7
24. Maggs JL, Bishop LPD, Edwards G, et al. Biliary metabolites of β-artemether in rats: biotransformations of an antimalarial endoperoxide. Drug Metab Dispos 1999; 28 (2): 209-16
25. Ramu K, Baker JK. Identification of the glucuronides of the hydroxylated metabolites of the antimalarial arteether in rat plasma and urine by thermospray high performance liquid chromatography/mass spectrometry. J Pharm Sci 1997; 86 (8): 915-27
26. Navaratnam V, Mansor SM, Sit N-W, et al. Pharmacokinetics of artemisinin type compounds. Clin Pharmacokinet 2000; 39 (4): 255-70
27. Grace JM, Aguilar AJ, Trotman KM, et al. Metabolism of β-arteether to dihydroartemisinin by human liver microsomes and recombinant cytochrome P450. Drug Metab Dispos 1997; 26 (4): 313-7
28. Sabarinath S, Rajanikanth M, Madhusudanan KP, et al. A sensitive and selective liquid chromatographic/electrospray ionization tandem mass spectrometric assay for the simultaneous quantification of α-, β-arteether and its metabolite dihydroartemisinin in plasma, useful for pharmacokinetic studies. J Mass Spectrom 2003; 38: 732-42
29. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000; 17: 1551-9
30. Rieckmann KH, Sax LJ, Campbell GH, et al. Drug sensitivity of P. falciparum, an in vitro microtechnique. Lancet 1978; I: 22-3
31. Okoyeh JN, Pillai CR, Chitnis CE. Plasmodium falciparum field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycoprotein A. Infect Immun 1999; 67: 5784-91
32. Lambros C, Vanderberg JP. Synchronisation of P. falciparum erythrocytic stage in culture. J Parasitol 1979; 65: 418-21
33. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamics (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355-8
34. Ludden TM, Beal SL, Sheiner LB. Comparison of Akaike Information Criterion, the Schwar Criterion and the F-test as guides to model selection. J Pharmacokinet Biopharm 1994; 22 (5): 431-45
35. Basco LK, Le Bras J. In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1993; 49 (3): 301-7
36. Wu Y. How might Qinghaosu and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc Chem Res 2002; 35 (5): 255-9
37. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32: 1655-60
38. Olliaro PL, Haynes RK, Meunier B, et al. Possible modes of action of the artemisinin type compounds. Trends Parasitol 2001; 17: 122-6
39. Ludwig UE, Webb RJ, van Gothem IDA, et al. Artemisinins target SERCA of Plasmodium falciparum. Nature 2003; 424: 957-61
40. Gibaldi M, Perrier D. Pharmacokinetics. 2nd rev. ed. New York: Marcel Dekker Inc., 1982
41. Puri SK, Srivastava K. In vitro evaluation of artemisinin derivatives in plasmodium strains. Lucknow: Parasitology Division, Central Drug Research Institute, 2004. (Data on file)
42. Li QG, Mog SR, Si YZ, et al. Neurotoxicity and efficacy of arteether related to its exposure times and levels in rodents. Am J Trop Med Hyg 2002; 66 (5): 516-25
43. Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994; 51 (3): 251-9
44. Toutain PL, del Castillo JRE, Bousquet-Melou A. The pharmacokinetic- pharmacodynamic approach to a rational dosage regimen for antibiotics. Res Vet Sci 2002; 73: 105-14
45. AliAbadi FS, Lees P. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimization. Int J Antimicrob Agents 2000; 14: 307-13
46. Dutta GP, Bajpai R, Vishwakarma RA. Comparison of antimalarial efficacy of artemisinin (Qinghaosu) and arteether against Plasmodium cyanomolgi B infection in monkeys. Trans R Soc Trop Med Hyg 1989; 83: 56-67